Literature DB >> 14991604

Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo.

Wojciech Dawicki1, Tania H Watts1.   

Abstract

4-1BBL(-/-) mice have a defect in recall CD8+ T cell responses to viruses, whereas CD4+ T cell responses to virus are unimpaired in these mice. In contrast, both CD4+ and CD8+ T cells respond to 4-1BB ligand (4-1BBL) in vitro. To clarify the role of 4-1BB/4-1BBL in CD4+ versus CD8+ T cell responses in vivo, we compared CD4 (OT-II) and CD8 (OT-I) TCR transgenic T cells responding to the same antigen in an in vivo adoptive transfer model in 4-1BBL(+/+) versus 4-1BBL(-/-) mice. During primary and secondary responses, expression of 4-1BB on in vivo-activated TCR transgenic T cells was earlier and more transient than previously observed in vitro, correlating with expression of the early activation antigen CD69 and preceding the transition to the CD44hi state. Although 4-1BB is expressed early in the primary response, there was no effect of 4-1BBL deficiency on initial CD8 T cell expansion and only a minor effect on initial CD4 T cell expansion. The major effect of 4-1BB/4-1BBL interaction is on the T cell recall response. This is due to effects of 4-1BBL on maintenance of T cell numbers at the end of the primary response with additional effects of 4-1BBL on secondary expansion of T cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991604     DOI: 10.1002/eji.200324278

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  33 in total

1.  CD137: costimulator turns suppressor?

Authors:  Aymen Al-Shamkhani
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

2.  Depletion of Tregs for adoptive T-cell therapy using CD44 and CD137 as selection markers.

Authors:  Brian G Till; Oliver W Press
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

3.  Differential ability of surface and endosomal TLRs to induce CD8 T cell responses in vivo.

Authors:  Rajakumar Mandraju; Sean Murray; James Forman; Chandrashekhar Pasare
Journal:  J Immunol       Date:  2014-03-31       Impact factor: 5.422

Review 4.  T-cell costimulatory blockade in organ transplantation.

Authors:  Jonathan S Maltzman; Laurence A Turka
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

5.  CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells.

Authors:  Shelly J Robertson; Ronald J Messer; Aaron B Carmody; Robert S Mittler; Christopher Burlak; Kim J Hasenkrug
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

6.  An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.

Authors:  Payal Mittal; Rebecca Abblett; Joseph M Ryan; Adam T Hagymasi; Archibald Agyekum-Yamoah; Julia Svedova; Steven L Reiner; Marie-Clare St Rose; Matthew P Hanley; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2018-01-05       Impact factor: 5.422

Review 7.  Modulation of GITR for cancer immunotherapy.

Authors:  David A Schaer; Judith T Murphy; Jedd D Wolchok
Journal:  Curr Opin Immunol       Date:  2012-01-12       Impact factor: 7.486

8.  Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities.

Authors:  Matthias Wolfl; Jürgen Kuball; William Y Ho; Hieu Nguyen; Thomas J Manley; Marie Bleakley; Philip D Greenberg
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

Review 9.  Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities.

Authors:  Matthias Wölfl; Jürgen Kuball; Matthias Eyrich; Paul G Schlegel; Philip D Greenberg
Journal:  Cytometry A       Date:  2008-11       Impact factor: 4.355

10.  IFN-gamma-indoleamine-2,3 dioxygenase acts as a major suppressive factor in 4-1BB-mediated immune suppression in vivo.

Authors:  Young H Kim; Beom K Choi; Woo J Kang; Kwang H Kim; Sang W Kang; Andrew L Mellor; David H Munn; Byoung S Kwon
Journal:  J Leukoc Biol       Date:  2009-02-13       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.